SG176581A1 - New therapeutical uses of inecalcitol - Google Patents
New therapeutical uses of inecalcitol Download PDFInfo
- Publication number
- SG176581A1 SG176581A1 SG2011085776A SG2011085776A SG176581A1 SG 176581 A1 SG176581 A1 SG 176581A1 SG 2011085776 A SG2011085776 A SG 2011085776A SG 2011085776 A SG2011085776 A SG 2011085776A SG 176581 A1 SG176581 A1 SG 176581A1
- Authority
- SG
- Singapore
- Prior art keywords
- inecalcitol
- day
- use according
- anyone
- administration
- Prior art date
Links
- BUDPDEVHCQIFNU-PUBYVPDWSA-N inecalcitol Chemical compound C1(/[C@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC#CC(C)(C)O)C)=C/C=C1/C[C@@H](O)C[C@H](O)C1=C BUDPDEVHCQIFNU-PUBYVPDWSA-N 0.000 title claims abstract description 66
- 229950003028 inecalcitol Drugs 0.000 title claims abstract description 66
- 230000001225 therapeutic effect Effects 0.000 title description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 20
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 19
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 19
- 239000011710 vitamin D Substances 0.000 claims abstract description 19
- 229940046008 vitamin d Drugs 0.000 claims abstract description 19
- 201000011510 cancer Diseases 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 8
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract description 7
- 201000002980 Hyperparathyroidism Diseases 0.000 claims abstract description 7
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 6
- 208000005368 osteomalacia Diseases 0.000 claims abstract description 6
- 208000007442 rickets Diseases 0.000 claims abstract description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000001028 anti-proliverative effect Effects 0.000 claims description 4
- 230000035563 calcemia Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000003262 anti-osteoporosis Effects 0.000 claims description 2
- 230000002682 anti-psoriatic effect Effects 0.000 claims description 2
- 239000013059 antihormonal agent Substances 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 12
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 12
- 208000037147 Hypercalcaemia Diseases 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000000148 hypercalcaemia Effects 0.000 description 10
- 208000030915 hypercalcemia disease Diseases 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 6
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 6
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 6
- 235000020964 calcitriol Nutrition 0.000 description 6
- 239000011612 calcitriol Substances 0.000 description 6
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 6
- 229960005084 calcitriol Drugs 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 150000001668 calcitriol derivatives Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 231100000041 toxicology testing Toxicity 0.000 description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 230000000125 calcaemic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 230000000121 hypercalcemic effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 2
- 229960000413 doxercalciferol Drugs 0.000 description 2
- HKXBNHCUPKIYDM-CGMHZMFXSA-N doxercalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C HKXBNHCUPKIYDM-CGMHZMFXSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 239000013081 microcrystal Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 229960000987 paricalcitol Drugs 0.000 description 2
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000607 toxicokinetics Toxicity 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 102000009310 vitamin D receptors Human genes 0.000 description 2
- 108050000156 vitamin D receptors Proteins 0.000 description 2
- LRLWXBHFPGSUOX-GJQYOBCGSA-N (1r,3z,5s)-3-[(2e)-2-[(3as,7as)-1-[(e,2s)-6-ethyl-6-hydroxyoct-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3h-inden-4-ylidene]ethylidene]-5-fluoro-4-methylidenecyclohexan-1-ol Chemical compound C1(/[C@@H]2CC=C([C@]2(CCC1)C)[C@@H](C)C/C=C/C(O)(CC)CC)=C\C=C1\C[C@@H](O)C[C@H](F)C1=C LRLWXBHFPGSUOX-GJQYOBCGSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229960001164 apremilast Drugs 0.000 description 1
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960002874 briakinumab Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940038717 copaxone Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229950001861 elocalcitol Drugs 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000002050 international nonproprietary name Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229960004577 laquinimod Drugs 0.000 description 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004079 mineral homeostasis Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- LVLLALCJVJNGQQ-ZCPUWASBSA-N seocalcitol Chemical compound C1(/[C@H]2CC[C@@H]([C@@]2(CCC1)C)[C@H](C)/C=C/C=C/C(O)(CC)CC)=C/C=C1/C[C@H](O)C[C@@H](O)C1=C LVLLALCJVJNGQQ-ZCPUWASBSA-N 0.000 description 1
- 229950009921 seocalcitol Drugs 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960000331 teriflunomide Drugs 0.000 description 1
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100001072 toxicokinetic profile Toxicity 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- -1 voclosporine Chemical compound 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17990609P | 2009-05-20 | 2009-05-20 | |
| PCT/EP2010/056832 WO2010145903A1 (en) | 2009-05-20 | 2010-05-18 | New therapeutical uses of inecalcitol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG176581A1 true SG176581A1 (en) | 2012-01-30 |
Family
ID=42308305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011085776A SG176581A1 (en) | 2009-05-20 | 2010-05-18 | New therapeutical uses of inecalcitol |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8481514B2 (enExample) |
| EP (1) | EP2263677B1 (enExample) |
| JP (2) | JP2012527424A (enExample) |
| KR (1) | KR101845320B1 (enExample) |
| CN (1) | CN102448466A (enExample) |
| AT (1) | ATE505194T1 (enExample) |
| AU (1) | AU2010261967B2 (enExample) |
| BR (1) | BRPI1009056A2 (enExample) |
| CA (1) | CA2762458C (enExample) |
| DE (1) | DE602010000019D1 (enExample) |
| DK (1) | DK2263677T3 (enExample) |
| ES (1) | ES2363070T3 (enExample) |
| HR (1) | HRP20110433T1 (enExample) |
| IL (1) | IL216418A (enExample) |
| MX (1) | MX2011012330A (enExample) |
| NZ (1) | NZ596497A (enExample) |
| PL (1) | PL2263677T3 (enExample) |
| PT (1) | PT2263677E (enExample) |
| RU (1) | RU2571490C2 (enExample) |
| SG (1) | SG176581A1 (enExample) |
| SI (1) | SI2263677T1 (enExample) |
| UA (1) | UA105792C2 (enExample) |
| WO (1) | WO2010145903A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2360145T3 (pl) | 2010-01-26 | 2012-08-31 | Hybrigenics Sa | Nowy sposób izomeryzacji skondensowanych struktur bicyklicznych oraz wytwarzania zawierających te struktury analogów witaminy D |
| EP2407152A1 (en) * | 2010-07-15 | 2012-01-18 | Hybrigenics S.A. | Formulations of 14-epi-analogues of vitamin D |
| SI2407155T1 (sl) * | 2010-07-15 | 2013-04-30 | Hybrigenics S.A. | Preparati na osnovi inekalcitola |
| US20120015913A1 (en) | 2010-07-15 | 2012-01-19 | Delansorne Remi | Formulations of 14-EPI-Analogues of Vitamin D |
| US10111896B2 (en) | 2014-06-19 | 2018-10-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Composition comprising a combination of DNA methylation inhibitor and a vitamin D receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse |
| IL262565B (en) | 2016-06-06 | 2022-08-01 | Celgene Corp | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| JP2020143008A (ja) * | 2019-03-05 | 2020-09-10 | 達也 楠堂 | 新規褐色脂肪細胞分化誘導剤 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0707566T3 (da) | 1993-07-09 | 2000-09-04 | Theramex | Hidtil ukendte strukturelle analoger til vitamin D |
| US6242434B1 (en) * | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
| GB0305332D0 (en) * | 2003-03-10 | 2003-04-09 | Leuven K U Res & Dev | Biological evaluation of novel vitamin D analogues |
| JP2008514621A (ja) * | 2004-09-24 | 2008-05-08 | ビオクセル エッセ ピ ア | ２０−シクロアルキル，２６，２７−アルキル／ハロアルキル−ビタミンｄ３化合物及びその使用方法 |
-
2010
- 2010-05-18 BR BRPI1009056-8A patent/BRPI1009056A2/pt not_active Application Discontinuation
- 2010-05-18 DK DK10163156.2T patent/DK2263677T3/da active
- 2010-05-18 PL PL10163156T patent/PL2263677T3/pl unknown
- 2010-05-18 UA UAA201113630A patent/UA105792C2/uk unknown
- 2010-05-18 CN CN2010800222064A patent/CN102448466A/zh active Pending
- 2010-05-18 DE DE602010000019T patent/DE602010000019D1/de active Active
- 2010-05-18 AU AU2010261967A patent/AU2010261967B2/en not_active Ceased
- 2010-05-18 US US12/782,301 patent/US8481514B2/en not_active Expired - Fee Related
- 2010-05-18 CA CA2762458A patent/CA2762458C/en not_active Expired - Fee Related
- 2010-05-18 RU RU2011151854/15A patent/RU2571490C2/ru not_active IP Right Cessation
- 2010-05-18 ES ES10163156T patent/ES2363070T3/es active Active
- 2010-05-18 SI SI201030002T patent/SI2263677T1/sl unknown
- 2010-05-18 KR KR1020117030464A patent/KR101845320B1/ko not_active Expired - Fee Related
- 2010-05-18 NZ NZ596497A patent/NZ596497A/xx not_active IP Right Cessation
- 2010-05-18 MX MX2011012330A patent/MX2011012330A/es active IP Right Grant
- 2010-05-18 EP EP10163156A patent/EP2263677B1/en active Active
- 2010-05-18 PT PT10163156T patent/PT2263677E/pt unknown
- 2010-05-18 JP JP2012511265A patent/JP2012527424A/ja active Pending
- 2010-05-18 AT AT10163156T patent/ATE505194T1/de active
- 2010-05-18 SG SG2011085776A patent/SG176581A1/en unknown
- 2010-05-18 WO PCT/EP2010/056832 patent/WO2010145903A1/en not_active Ceased
-
2011
- 2011-06-09 HR HR20110433T patent/HRP20110433T1/hr unknown
- 2011-11-17 IL IL216418A patent/IL216418A/en not_active IP Right Cessation
-
2016
- 2016-06-09 JP JP2016115489A patent/JP2016179994A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE602010000019D1 (de) | 2011-05-26 |
| CN102448466A (zh) | 2012-05-09 |
| DK2263677T3 (da) | 2011-06-06 |
| JP2012527424A (ja) | 2012-11-08 |
| ES2363070T3 (es) | 2011-07-19 |
| RU2011151854A (ru) | 2013-06-27 |
| IL216418A (en) | 2015-09-24 |
| SI2263677T1 (sl) | 2011-07-29 |
| MX2011012330A (es) | 2011-12-16 |
| CA2762458C (en) | 2018-08-28 |
| PT2263677E (pt) | 2011-06-01 |
| RU2571490C2 (ru) | 2015-12-20 |
| PL2263677T3 (pl) | 2011-09-30 |
| IL216418A0 (en) | 2012-02-29 |
| JP2016179994A (ja) | 2016-10-13 |
| EP2263677A1 (en) | 2010-12-22 |
| AU2010261967B2 (en) | 2016-03-03 |
| US8481514B2 (en) | 2013-07-09 |
| CA2762458A1 (en) | 2010-12-23 |
| WO2010145903A1 (en) | 2010-12-23 |
| AU2010261967A1 (en) | 2011-12-08 |
| ATE505194T1 (de) | 2011-04-15 |
| UA105792C2 (uk) | 2014-06-25 |
| BRPI1009056A2 (pt) | 2020-06-02 |
| HRP20110433T1 (hr) | 2011-07-31 |
| KR20120017075A (ko) | 2012-02-27 |
| KR101845320B1 (ko) | 2018-04-04 |
| US20110015276A1 (en) | 2011-01-20 |
| NZ596497A (en) | 2013-05-31 |
| EP2263677B1 (en) | 2011-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2762458C (en) | New therapeutical uses of inecalcitol | |
| EP0951286B1 (en) | Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations | |
| JP2005510536A (ja) | 活性ビタミンｄ類縁物質を使用した過剰増殖性疾病の治療 | |
| NZ336508A (en) | Method of treating prostatic diseases using active vitamin d analogues | |
| US7094775B2 (en) | Method of treating breast cancer using a combination of vitamin D analogues and other agents | |
| AU2004220622A1 (en) | Method of treating and preventing hyperparathyroidism with vitamin D2 or D4 compounds | |
| CN101848708B (zh) | 皮质类固醇用于制备治疗埃坡霉素或埃坡霉素衍生物诱导的腹泻的药物 | |
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| KR101628448B1 (ko) | 암 치료에 사용하기 위한 베무라페닙 및 인터페론을 포함하는 병용 요법 | |
| US11026906B2 (en) | Pharmaceutical quality strontium L-lactate | |
| JP4672257B2 (ja) | エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用 | |
| ES2398640T3 (es) | Formulaciones de análogos 14-epi de la vitamina D | |
| US20120101057A1 (en) | Combined therapy of colorectal carcinoma | |
| EP0215956A1 (en) | Composition for treating skin disease | |
| AU2003291294A1 (en) | Methods of using vitamin d compounds in the treatment of myelodysplastic syndromes | |
| KR20010092751A (ko) | 다발성 골수종의 골 병변 치료용 의약 조성물 | |
| US9913816B2 (en) | Method for applying metformin and sodium butyrate in K-ras mutation cancer treatment | |
| UA112845C2 (uk) | Склад 14-eпi-аналогів вітаміну d | |
| JPH11116501A (ja) | 骨吸収関連疾患治療剤 |